Detalhe da pesquisa
1.
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
Blood
; 142(17): 1438-1447, 2023 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37418685
2.
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.
Blood
; 140(12): 1378-1389, 2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737911
3.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Haematologica
; 109(2): 553-566, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646664
4.
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Haematologica
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497158
5.
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385243
6.
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.
Eur J Nucl Med Mol Imaging
; 2024 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38795120
7.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36632738
8.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol
; 108(1): 73-83, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496096
9.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Lancet
; 395(10218): 132-141, 2020 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31836199
10.
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407608
11.
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
Haematologica
; 106(4): 1079-1085, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107329
12.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 106(9): 2417-2426, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196165
13.
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
BMC Cancer
; 21(1): 659, 2021 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34078314
14.
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Ann Hematol
; 100(10): 2547-2556, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34327561
15.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol
; 21(7): 978-988, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32511983
16.
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Br J Haematol
; 189(5): 888-903, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32017044
17.
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.
Haematologica
; 105(1): 193-200, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31221778
18.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Haematologica
; 105(4): 1074-1080, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31248973
19.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(6): 781-794, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097405
20.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Cancer
; 125(5): 750-760, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30561775